# A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Study · id `cardio:ct-nct01621178` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01621178](<https://clinicaltrials.gov/study/NCT01621178>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01621178

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.

## Technical summary

Registry record NCT01621178. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2016-06 (actual). Results posted on 2017-07-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 577 participants (enrolled count; ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Primary completion: 2016-06 (actual) (ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Results first posted: 2017-07-24 (ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Countries: United States; Brazil; Hungary; Mexico; Poland; Romania; South Africa; Spain; Ukraine (ClinicalTrials.gov record NCT01621178, source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01621178-2019-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
- Acronym: AWARD-7
- Condition: Type 2 Diabetes
- Condition: Chronic Kidney Disease
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Insulin lispro
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial (`cardio:pubmed-29910024`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bc227bb26e6e25b1d77de11b004426a71e775825ae44e46b97c8d23439a8b78d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
